SCHEMBL4151365

SCHEMBL4151365

O=S(=O)(c1ccccc1)c1ccc2[nH]c(-c3ccc(F)cc3F)cc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.48
HTR2C P28335 2/20 0.48
KCNH2 Q12809 2/20 0.48
ALDH1A1 P00352 3/20 0.43
HPGD P15428 3/20 0.43
MEN1 O00255 1/20 0.43
THRB P10828 1/20 0.43
KMT2A Q03164 1/20 0.43
FFAR1 O14842 2/20 0.43
SCN9A Q15858 1/20 0.42
PPARG P37231 1/20 0.41
MAPT P10636 1/20 0.39
KDR P35968 2/20 0.39
CYP1A1 P04798 1/20 0.39
KIT P10721 1/20 0.38
CNR1 P21554 1/20 0.37
KDM4E B2RXH2 2/20 0.37
LMNA P02545 2/20 0.37
PDPK1 O15530 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4154662 0.88 FFAR1 (0.54) HTR2AHTR2CKCNH2FFAR1SCN9A
SCHEMBL4158621 0.83 CA12 (0.51) HTR2AHTR2CKCNH2ALDH1A1HPGD
SCHEMBL4147377 0.78 CYP19A1 (0.56) ALDH1A1HPGDMEN1KMT2APPARG
SCHEMBL27867018 0.73 KDM4E (0.47) HTR2AHTR2CKCNH2ALDH1A1HPGD
SCHEMBL4066217 0.72 HTR2A (0.54) HTR2AHTR2CKCNH2ALDH1A1HPGD
SCHEMBL4150984 0.72 HTR2A (0.43) HTR2AHTR2CKCNH2ALDH1A1HPGD
SCHEMBL3390895 0.70 HTR2A (0.51) HTR2AHTR2CKCNH2ALDH1A1MAPT
SCHEMBL23298986 0.70 ALDH1A1 (0.62) ALDH1A1HPGDMEN1THRBKMT2A
SCHEMBL1993674 0.69 HTR2A (0.50) HTR2AHTR2CKCNH2ALDH1A1HPGD
SCHEMBL778229 0.67 HTR6 (0.70) HTR2AHTR2CKCNH2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090012134-A1 Arylsulfonyl Benzofused Heterocycles as 5-Ht2a Antagonists CURTIS NEIL ROY 2009-01-08 US claimed
US-20090012134-A1 Arylsulfonyl Benzofused Heterocycles as 5-Ht2a Antagonists CURTIS NEIL ROY 2009-01-08 US disclosed
EP-1866300-A1 ARYLSULFONYL BENZOFUSED HETEROCYCLES AS 5-HT2A ANTAGONISTS MERCK SHARP & DOHME LTD. (GB) 2007-12-19 EP disclosed
WO-2006100519-A1 ARYLSULFONYL BENZOFUSED HETEROCYCLES AS 5-HT2A ANTAGONISTS MERCK SHARP & DOHME LIMITED (GB) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012134-A1 Arylsulfonyl Benzofused Heterocycles as 5-Ht2a Antagonists HTR2A, HTR2C, HTR2B HTR2A 1/4885HTR2C 2/4885KCNH2 544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.